Publications

Export 108 results:
Auteur Title [ Type(Desc)] Année
Filtres: Auteur is Serge Gauthier  [Enlever les filtres]
Journal Article
Zimmer ER, Parent MJ, Souza DG, Leuzy A, Lecrux C, Kim H-I, Gauthier S, Pellerin L, Hamel E, Rosa-Neto P.  2017.  [(18)F]FDG PET signal is driven by astroglial glutamate transport.. Nat Neurosci. 20(3):393-395.
Pascoal TA, Therriault J, Benedet AL, Savard M, Lussier FZ, Chamoun M, Tissot C, Qureshi MNaveed Iqb, Kang MSu, Mathotaarachchi S et al..  2020.  18F-MK-6240 PET for early and late detection of neurofibrillary tangles.. Brain. 143(9):2818-2830.
Levy JP, Bezgin G, Savard M, Pascoal TA, Finger E, Laforce R, Sonnen JA, Soucy J-P, Gauthier S, Rosa-Neto P et al..  2021.  18F-MK-6240 tau-PET in genetic frontotemporal dementia.. Brain.
Gonneaud J, Baria AT, Binette APichet, Gordon BA, Chhatwal JP, Cruchaga C, Jucker M, Levin J, Salloway S, Farlow M et al..  2021.  Accelerated functional brain aging in pre-clinical familial Alzheimer's disease.. Nat Commun. 12(1):5346.
Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JLuis, Blennow K, DeKosky ST, Gauthier S, Selkoe D, Bateman R et al..  2014.  Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria.. Lancet Neurol. 13(6):614-29.
Cummings J, Mintzer J, Brodaty H, Sano M, Banerjee S, Devanand DP, Gauthier S, Howard R, Lanctôt K, Lyketsos CG et al..  2015.  Agitation in cognitive disorders: International Psychogeriatric Association provisional consensus clinical and research definition.. Int Psychogeriatr. 27(1):7-17.
Pascoal TA, Mathotaarachchi S, Shin M, Park AYeon, Mohades S, Benedet AL, Kang MSu, Massarweh G, Soucy J-P, Gauthier S et al..  2018.  Amyloid and tau signatures of brain metabolic decline in preclinical Alzheimer's disease.. Eur J Nucl Med Mol Imaging. 45(6):1021-1030.
Kang MSu, Aliaga AAliaga, Shin M, Mathotaarachchi S, Benedet AL, Pascoal TA, Therriault J, Chamoun M, Savard M, Devenyi GA et al..  2020.  Amyloid-beta modulates the association between neurofilament light chain and brain atrophy in Alzheimer's disease.. Mol Psychiatry.
Therriault J, Pascoal TA, Sefranek M, Mathotaarachchi S, Benedet AL, Chamoun M, Lussier FZ, Tissot C, Bellaver B, Lukasewicz PS et al..  2021.  Amyloid-dependent and amyloid-independent effects of Tau in individuals without dementia.. Ann Clin Transl Neurol. 8(10):2083-2092.
Pascoal TA, Mathotaarachchi S, Mohades S, Benedet AL, Chung C-O, Shin M, Wang S, Beaudry T, Kang MS, Soucy J-P et al..  2016.  Amyloid-β and hyperphosphorylated tau synergy drives metabolic decline in preclinical Alzheimer's disease.. Mol Psychiatry.
Therriault J, Ng KPin, Pascoal TA, Mathotaarachchi S, Kang MSu, Struyfs H, Shin M, Benedet AL, Walpola IC, Nair V et al..  2018.  Anosognosia predicts default mode network hypometabolism and clinical progression to dementia.. Neurology. 90(11):e932-e939.
Ba M, Kong M, Li X, Ng KPin, Rosa-Neto P, Gauthier S.  2016.  Is ApoE ɛ 4 a good biomarker for amyloid pathology in late onset Alzheimer's disease? Transl Neurodegener. 5:20.
Therriault J, Benedet AL, Pascoal TA, Mathotaarachchi S, Savard M, Chamoun M, Thomas É, Kang MSu, Lussier F, Tissot C et al..  2020.  APOEε4 potentiates the relationship between amyloid-β and tau pathologies.. Mol Psychiatry.
Lajoie I, Nugent S, Debacker C, Dyson K, Tancredi FB, Badhwar AP, Belleville S, Deschaintre Y, Bellec P, Doyon J et al..  2017.  Application of calibrated fMRI in Alzheimer's disease.. Neuroimage Clin. 15:348-358.
Tissot C, Therriault J, Pascoal TA, Chamoun M, Lussier FZ, Savard M, Mathotaarachchi SS, Benedet AL, Thomas EM, Parsons M et al..  2021.  Association between regional tau pathology and neuropsychiatric symptoms in aging and dementia due to Alzheimer's disease.. Alzheimers Dement (N Y). 7(1):e12154.
Gauthier S, Ng KPin, Pascoal TA, Mathotaarachchi S, Chung C-O, Benedetti AL, Shin M, Kang MSu, Li X, Ba M et al..  2017.  Author response: Neuropsychiatric symptoms predict hypometabolism in preclinical Alzheimer disease.. Neurology. 89(18):1931.
Brayet P, Petit D, Baril A-A, Gosselin N, Gagnon J-F, Soucy J-P, Gauthier S, Kergoat M-J, Carrier J, Rouleau I et al..  2017.  Brain perfusion during rapid-eye-movement sleep successfully identifies amnestic mild cognitive impairment.. Sleep Med. 34:134-140.
Laforce R, Rosa-Neto P, Soucy J-P, Rabinovici GD, Dubois B, Gauthier S.  2016.  Canadian Consensus Guidelines on Use of Amyloid Imaging in Canada: Update and Future Directions from the Specialized Task Force on Amyloid imaging in Canada.. Can J Neurol Sci. 43(4):503-12.
Gauthier S, Proaño JVoltaire, Jia J, Froelich L, Vester JChristophe, Doppler E.  2015.  Cerebrolysin in mild-to-moderate Alzheimer's disease: a meta-analysis of randomized controlled clinical trials.. Dement Geriatr Cogn Disord. 39(5-6):332-47.
Li X, Ba M, Ng KPin, Mathotaarachchi S, Pascoal TA, Rosa-Neto P, Gauthier S.  2018.  Characterizing biomarker features of cognitively normal individuals with ventriculomegaly.. Alzheimers Dement (Amst). 10:12-21.
Sinyavskaya L, Gauthier S, Renoux C, Dell'Aniello S, Suissa S, Brassard P.  2018.  Comparative effect of statins on the risk of incident Alzheimer disease.. Neurology. 90(3):e179-e187.
Chertkow H, Borrie M, Whitehead V, Black SE, Feldman HH, Gauthier S, Hogan DB, Masellis M, McGilton K, Rockwood K et al..  2019.  The Comprehensive Assessment of Neurodegeneration and Dementia: Canadian Cohort Study.. Can J Neurol Sci. 46(5):499-511.
Shiells H, Schelter BO, Bentham P, Baddeley TC, Rubino CM, Ganesan H, Hammel J, Vuksanovic V, Staff RT, Murray AD et al..  2020.  Concentration-Dependent Activity of Hydromethylthionine on Clinical Decline and Brain Atrophy in a Randomized Controlled Trial in Behavioral Variant Frontotemporal Dementia.. J Alzheimers Dis. 75(2):501-519.
Schelter BO, Shiells H, Baddeley TC, Rubino CM, Ganesan H, Hammel J, Vuksanovic V, Staff RT, Murray AD, Bracoud L et al..  2019.  Concentration-Dependent Activity of Hydromethylthionine on Cognitive Decline and Brain Atrophy in Mild to Moderate Alzheimer's Disease.. J Alzheimers Dis. 72(3):931-946.

Pages